<DOC>
	<DOCNO>NCT01883362</DOCNO>
	<brief_summary>To determine addition midostaurin ( PKC412 ) Standard Care ( SOC ) therapy reduces relapse FLT3-ITD mutate AML patient receive allogenetic hematopoietic stem cell transplant ,</brief_summary>
	<brief_title>Standard Care +/- Midostaurin Prevent Relapse Post Stem Cell Transplant Patients With FLT3-ITD Mutated AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>4'-N-benzoylstaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>Patients must 18 60 year age Patients must ECOG Performance Status &lt; 2 Patients must document Unequivocal diagnosis AML accord WHO 2008 classification ( &gt; 20 % blast bone marrow ) , exclude M3 ( acute promyelocytic leukemia ) . Patients must document FLT3 ITD mutation , determine local laboratory eligibility ( historical tissue request central analysis confirmation ) Patients undergone allogeneic HSCT CR1 match relate matched unrelated donor . All following criterion must also meet : HLA type include available 8/8 7/8 allele HLA match donor ( A , B , C , DRB1 ) Single allelic mismatch allow • Patients receive condition regimen include one following : Busulfan/Fludarabine ( Bu/Flu ) Busulfan ( 16 mg/kg PO 12.8 mg/kg IV ) Fludarabine ( 120180 mg/m2 ) Fludarabine / Melphalan ( Flu/Mel ) Fludarabine ( 120180 mg/m2 ) Melphalan ( ≤ 150 mg/m2 ) Busulfan/Cyclophosphamide ( Bu/Cy ) Busulfan ( 16 mg/kg PO 12.8 mg/kg IV ) Cyclophosphamide ( 120 mg/kg ) Cyclophosphamide/Total Body Irradiation ( Cy/TBI ) Cyclophosphamide ( 120 mg/kg ) TBI ( 12001420 cGy ) • Recovery count day 42 able start midostaurin day 60 postHSCT ( first dose midostaurin start early 28 day postHSCT ) ; ANC &gt; 1000µL , platelet ≥20,000 without platelet transfusion Patients fail prior attempt allogeneic HSCT Patients receive autologous transplant Patients Acute GVHD Grade IIIIV Patients know confirmed diagnosis HIV infection active viral hepatitis . Impaired cardiac function include follow : Screening ECG QTc &gt; 450 msec . If QTc &gt; 450 electrolyte within normal range , electrolyte correct patient rescreened QTc . Patients congenital long QT syndrome History presence sustain ventricular tachycardia Any history ventricular fibrillation torsades de pointes Bradycardia define HR . &lt; 50 bpm Right bundle branch block + leave anterior hemiblock ( bifascicular block ) Patients myocardial infarction unstable angina &lt; 6 month prior start study Congestive Heart Failure NY Heart Association class III IV Patients ejection fraction &lt; 45 % assessed MUGA ECHO within 28 day prior start study cycle 1 ( midostaurin control group ) Patients pulmonary infiltrate include suspect infectious origin ( unless resolve ≤ Grade 1 within screen timeframe ) Patient require treatment strong CYP3A4 inhibitor moderate strong CYP3A4 inducer require GVH infection prophylaxis treatment Pregnant nursing ( lactate ) woman , woman childbearing potential , must use highly effective method contraception dose 30 day treatment completion Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>FLT3-ITD</keyword>
	<keyword>midostaurin</keyword>
	<keyword>PKC412</keyword>
	<keyword>allogeneic hematopoeitic stem cell tranplant</keyword>
	<keyword>SCT</keyword>
	<keyword>HSCT</keyword>
	<keyword>CR1</keyword>
</DOC>